NorGenoTech AS arose from the success of the EC project COMICS in making improved high throughput methods for analysis of DNA damage and repair. Our aim is to play a leading role in the field of DNA damage analysis in Europe, carrying out laboratory services, providing expertise and supplying modern equipment needed by the research, industry and healthcare.
The founders of the company, Professor Andrew Collins, Dr Gunnar Brunborg, Dr Amaya Azqueta and Dr Sergey Shaposhnikov are leading researchers in the DNA damage field responsible for numerous innovations. Vaineta Vebraite is our laboratory manager, and Chris Brøvig is a business generalist.
Our leading scientists have worked together for many years and are known for their innovative methods and novel applications of the comet assay. They are active in organising international workshops, conferences and training courses, and have unparalleled insight into the needs of the comet assay community and the scope for improvement in several aspects of the technique.
We benefit from international collaborations with renowned scientists, a highly skilled
research environment and access to modern laboratory facilities.
While maintaining a lean, low overhead organization, we enjoy ready access to the scientific and administrative resources of large European universities, thus providing us with the flexibility to take on new projects on short notice. By way of example:
- We have trained over 100 young scientists from leading Universities all over Europe, which puts us in a privileged position of identifying and inviting the best students and researchers to join our workforce.
- Our closeness to the University of Oslo, Norwegian Radium hospital and the Norwegian Institute of Public health allows us to expand our team quickly to accommodate large-scale projects. We also benefit from the highly skilled and productive research environments of these institutions.
- Due to our extensive collaborations, we have access to laboratory facilities at various Universities in Europe which allows us to carry out clinical trials and specific projects in a cost- and time-efficient
Thus we combine the flexibility of a modern SME with administrative and technical resources from large Universities.